Guardant Health (GH) announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy, published in Cancer Research Communications. The data found that the Guardant Reveal test successfully detected responses to immunotherapy across multiple solid tumor types in advanced-stage cancer patients. The study also showed Guardant Reveal identified non-responders up to five months earlier than standard methods, supporting the use of blood-based monitoring to predict treatment response.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- ILMN, NVDA: Cathie Wood Pours Over 5 Million Into Biotech and AI Stocks, Cuts RKLB Stake Again
- Guardant Health announces patient enrollment in Vanguard Study
- Supreme Court keeps element of Obamacare preventive care, Reuters reports
- Guardant Health Elects Board and Approves Auditor
- Cathie Wood’s ARK Investment buys 99.6K shares of Guardant Health today